{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075190","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.461011+00:00","generated_at":"2026-05-17T14:00:14.759462+00:00","sec_items":["1.01","2.01","3.02","9.01","4.01","3.03","5.03","8.01","5.01","5.02","5.05","5.06","7.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds","bullets":["Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.","PIPE of $260.9M (24.3M shares at $10.7173) plus $120.9M trust; $76.3M redeemed by 7.1M public shares.","Pro forma shares: ~79.2M outstanding (excluding options); ~61.1M shares (77.2%) subject to registration rights.","Lock-up: Helix insiders 1 year; BBOT employees below VP 6 months; other BBOT holders 1 year.","Equity plans approved: 2025 Incentive Plan (5.37M shares + evergreen) and ESPP (0.9M shares + evergreen)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075190","json":"https://secwatch.observer/filing/0001213900-25-075190.json","markdown":"https://secwatch.observer/filing/0001213900-25-075190.md","text":"https://secwatch.observer/filing/0001213900-25-075190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea0250662-8k_bridge.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:00:14.759462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2601b71e73ab4c9bb6f4a48efb9641111a34342c","claim":"BridgeBio Oncology Therapeutics, Inc.: Approved and adopted a new Code of Ethics in connection with closing of the Business Combination.","evidence_excerpt":"In connection with the closing of the Business Combination, the PubCo Board approved and adopted a new Code of Ethics is applicable to all of PubCo’s employees, officers (including its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants, and will be available on PubCo’s website at https://www.bbotx.com.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"32eec34cefe45278f4b1b9e2f9b5ea2048403d65","claim":"BridgeBio Oncology Therapeutics, Inc.: Helix ceased to be a shell company upon closing of the Business Combination.","evidence_excerpt":"Upon the closing of the Business Combination, Helix ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"9840f36d1c3a3923710d77d0998a553403cbf14b","claim":"BridgeBio Oncology Therapeutics, Inc.: Adopted PubCo Charter effective upon filing with Delaware Secretary of State on August 11, 2025 (effective 2025-08-11).","evidence_excerpt":"The PubCo Charter, which became effective upon filing with the Secretary of State of the State of Delaware on August 11, 2025, includes the amendments proposed by the Domestication Proposal, the Organizational Documents Proposal and the Advisory Organizational Documents Proposals and approved at the EGM.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-11"}],"fact_type":"governance_change"},{"claim_id":"e0f07f2e600a36a31fe713dcdf60637420ee8625","claim":"BridgeBio Oncology Therapeutics, Inc.: Approved and adopted PubCo Bylaws effective as of the Effective Time on August 11, 2025 (effective 2025-08-11).","evidence_excerpt":"On August 11, 2025, the PubCo Board approved and adopted the PubCo Bylaws containing the amendments proposed by the Organizational Documents Proposal and Advisory Organizational Documents Proposal and approved at the EGM, which became effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-08-11"}],"fact_type":"governance_change"},{"claim_id":"acf393214394468a8913bedd13e7237a0e191be0","claim":"BridgeBio Oncology Therapeutics, Inc. completed an acquisition involving TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (closed 2025-08-11).","evidence_excerpt":"On August 11, 2025 (the “Closing Date”), Helix Acquisition Corp. II., a Cayman Islands exempted company (“Helix”), consummated the previously announced business combination pursuant to the terms of the business combination agreement, dated February 28, 2025 and amended on June 17, 2025 (as amended, the “Business Combination Agreement”), with Helix II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DYNS (“Merger Sub”), and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation (“BBOT”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics)"},{"label":"Closing","value":"2025-08-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}